[18F]MFBG PET/CT imaging of myocardial sympathetic innervation in healthy controls and patients with parkinson’s disease: dosimetry and pharmacokinetics
European Journal of Nuclear Medicine and Molecular Imaging · 2026
DOI: 10.1007/s00259-025-07517-3 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Louis Versweyveld und 7 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium. Louis.versweyveld@gmail.com. Hauptthemen laut MEDLINE: Heart, Parkinson Disease, Positron Emission Tomography Computed Tomography, Sympathetic Nervous System. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Fonds Wetenschappelijk Onderzoek.
Abstract (Originalsprache)
PURPOSE: Cardiac noradrenergic denervation visualized by meta-[123I]iodobenzylguanidine ([123I]MIBG) imaging supports the diagnosis of Parkinson's disease (PD). Recently, meta-[18F] fluorobenzylguanidine ([18F]MFBG) PET demonstrated favorable imaging characteristics compared with [123I]MIBG scintigraphy for neuroendocrine tumors. We assessed [18F]MFBG dosimetry and myocardial pharmacokinetics in healthy controls and PD patients. METHODS: For dosimetry, three controls underwent sequential whole-body [18F]MFBG PET/CT up to 6 hours postinjection. Five controls and three PD patients underwent 120-min dynamic cardiac [18F]MFBG PET/CT and two static [123I]MIBG SPECT/CT scans with planar scintigraphy, at 15 min and 3-4 h postinjection. An aortic image-derived input function with population-based radiometabolite corrections was validated against arterial sampling to derive myocardial distribution volume (VT) using a 2-tissue compartment model (2TCM). [18F]MFBG VT was assessed for time-stability and compared to heart-to-mediastinum ratio (HMR) for [18F]MFBG and [123I]MIBG. RESULTS: Mean effective dose was 23.1±2.6 μSv/MBq. [18F]MFBG exhibited rapid blood pool clearance and cardiac uptake, with VT of 35.1±10.6 mL/cm3 in controls and 5.9±1.6 mL/cm3 in PD. 2TCM VT from 30-min dynamic PET datasets starting at tracer injection showed strong agreement (mean difference -1.3 mL/cm3 and LoA=-7.1 mL/cm3 to 4.5 mL/cm3) and correlation (R2=0.97, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium. Louis.versweyveld@gmail.com.
- Department of Neurology, University Hospitals Leuven, Leuven, Belgium. Louis.versweyveld@gmail.com.
- Department of Neurology, University Hospitals Leuven, Leuven, Belgium.
- Department of Neurosciences, KU Leuven, Leuven, Belgium.
- Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
- Division of Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium.
ORCID-Profile: Louis Versweyveld
Förderung
- Fonds Wetenschappelijk Onderzoek
Zitieren
APA
Versweyveld, L., Delva, A., Cohilis, M., Deroose, C. M., Van Weehaeghe, D., Koole, M., Vandenberghe, W., & Van Laere, K. (2026). [18F]MFBG PET/CT imaging of myocardial sympathetic innervation in healthy controls and patients with parkinson’s disease: dosimetry and pharmacokinetics. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07517-3
Vancouver
Versweyveld L, Delva A, Cohilis M, Deroose CM, Van Weehaeghe D, Koole M, et al. [18F]MFBG PET/CT imaging of myocardial sympathetic innervation in healthy controls and patients with parkinson’s disease: dosimetry and pharmacokinetics. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-025-07517-3
BibTeX
@article{Versweyveld2026,
author = {Versweyveld, Louis and Delva, Aline and Cohilis, Marie and Deroose, Christophe M and Van Weehaeghe, Donatienne and Koole, Michel and Vandenberghe, Wim and Van Laere, Koen},
title = {[18F]MFBG PET/CT imaging of myocardial sympathetic innervation in healthy controls and patients with parkinson’s disease: dosimetry and pharmacokinetics},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
doi = {10.1007/s00259-025-07517-3}
}
EUVIMED